Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...
The development and regulatory approval of vemurafenib and dabrafenib for metastatic melanoma patients with activating BRAF mutations has demonstrated that personalized targeted therapy strategies can provide significant clinical benefit in this highly aggressive disease. However, these agents are n...
Main Author: | Michael A. Davies |
---|---|
Format: | Article |
Language: | English |
Published: |
Advocate Aurora Health
2014-01-01
|
Series: | Journal of Patient-Centered Research and Reviews |
Subjects: | |
Online Access: | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1006&context=jpcrr |
Similar Items
-
Advances in the treatment of advanced melanoma with NRAS gene mutation
by: ZHAO Bolun, ZHU Guannan
Published: (2023-10-01) -
Efficacy of Targeted Radionuclide Therapy Using [<sup>131</sup>I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
by: Hussein Akil, et al.
Published: (2021-03-01) -
Atypical <i>BRAF</i> and <i>NRAS</i> Mutations in Mucosal Melanoma
by: Nicolas Dumaz, et al.
Published: (2019-08-01) -
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
by: Ileabett M Echevarría‐Vargas, et al.
Published: (2018-05-01) -
Molecular Markers and Targets in Melanoma
by: Cristina Teixido, et al.
Published: (2021-09-01)